Abstract
Background During the COVID-19 pandemic, aerosol spread of SARS-CoV-2 has been a major problem in healthcare facilities, resulting in increased use of supplementary HEPA filtration to mitigate transmission. We report here a natural experiment that occurred when an air filtration unit (AFU) on an inpatient ward for older people was accidentally switched off.
Aim To assess aerosol transport within the ward and determine whether the AFU reduced particulate matter (PM) levels in the air.
Methods Time-series PM, CO2, temperature and humidity data (at 1 minute intervals) was collected from multiple sensors around the ward over two days in August 2021. During this period, the AFU was accidentally switched off for approximately 7 hours, allowing the impact of the intervention on particulates (PM1-PM10) to be assessed using a Mann-Whitney test. Pearson correlation analysis of the PM and CO2 signals was also undertaken to evaluate the movement of airborne particulates around the ward.
Findings The AFU greatly reduced PM counts of all sizes throughout the ward space (p<0.001 for all sensors), with PM signals positively correlated with indoor CO2 levels (r = 0.343 – 0.817; all p<0.001). Aerosol particle counts tended to rise and fall simultaneously throughout the ward space when the AFU was off, with PM signals from multiple locations highly correlated (e.g. r = 0.343 – 0.868 (all p<0.001) for PM1).
Conclusion Aerosols freely migrated between the various sub-compartments of the ward, suggesting that social distancing measures alone cannot prevent nosocomial transmission of SARS-CoV-2. The AFU greatly reduced PM levels throughout the ward space.
Practical implications
Aerosols can freely migrate throughout whole wards, suggesting that social distancing measures alone are not enough to prevent SARS-CoV-2 transmission.
Appropriately sized supplementary room air filtration, if utilised correctly, can greatly reduce aerosol levels throughout ward spaces.
Air filtration devices are often placed in rooms without any consideration given to their performance. It is therefore important to commission air filtration devices using PM and CO2 sensors before they are utilised in order to demonstrate that they are effective throughout entire ward spaces.
Competing Interest Statement
Darren Sloof is the founder, director and shareholder of Air Purity Ltd. Air Purity designed and supplied the air filtration units and air sensors used in this study. Air Purity Ltd had no role in the study design or analysis of the data. Darren Sloof did however collect the data and liaise with other authors over its interpretation. Dr Andrew Conway Morris is a member of the scientific advisory board of Cambridge Infection Diagnostics. Dr Theodore Gouliouris has received materials from Shionogi for conducting a laboratory evaluation. The other authors have no competing interests.
Funding Statement
The work presented in this manuscript was a preliminary study which subsequently led to a larger project which is ongoing, the Addenbrooke's Air Disinfection Study (AAirDS, Chief Investigator: Dr Victoria L Keevil). AAirDS is funded by the UK Health Security Agency and was approved by the NHS Health Research Authority and Health and Care Research Wales (HCRW) (IRAS ID 299336) and the Central Bristol Research Ethics Committee (REC reference: 22/SW/0010). Dr Victoria L Keevil is funded by a MRC/NIHR Clinical Academic Research Partnership Grant (CARP; grant code: MR/T023902/1). Dr Andrew Conway Morris is supported by a Clinician Scientist Fellowship from the Medical Research Council (MR/V006118/1). Air Purity Ltd. designed and supplied the air filtration units and air sensors used in this study. Air Purity Ltd had no role in the study design or analysis of the data. Darren Sloof, the founder, director and shareholder of Air Purity did however collect the data and liaise with other authors over its interpretation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Ethics, funding and permissions: The work presented in this manuscript did not constitute research under the UK Policy Framework for Health and Social Care Research and was not subject to formal ethical review. Subsequently, this work led to a larger project which is ongoing, the Addenbrooke’s Air Disinfection Study (AAirDS, Chief Investigator: Dr Victoria L Keevil). AAirDS is funded by the UK Health Security Agency and was approved by the NHS Health Research Authority and Health and Care Research Wales (HCRW) (IRAS ID 299336) and the Central Bristol Research Ethics Committee (REC reference: 22/SW/0010).
Dr Victoria L Keevil is funded by a MRC/NIHR Clinical Academic Research Partnership Grant (CARP; grant code: MR/T023902/1).
Dr Andrew Conway Morris is supported by a Clinician Scientist Fellowship from the Medical Research Council (MR/V006118/1).
Competing Interests: Darren Sloof is the founder, director and shareholder of Air Purity Ltd. Air Purity designed and supplied the air filtration units and air sensors used in this study. Air Purity Ltd had no role in the study design or analysis of the data. Darren Sloof did however collect the data and liaise with other authors over its interpretation.
Dr Andrew Conway Morris is a member of the scientific advisory board of Cambridge Infection Diagnostics.
Dr Theodore Gouliouris has received materials from Shionogi for conducting a laboratory evaluation.
The other authors have no competing interests.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
